Selective IgE deficiency and cardiovascular diseases

Magen, Eli; Mishal, Joseph; Vardy, Daniel

doi:10.2500/aap.2015.36.3825

Cited by 15 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cellular treatments, including selective modification of effector cells, represent an innovative technology for targeted therapy of allergic diseases [ 71 ]. Notwithstanding, there remains a serious concern that reducing patients’ IgE response ability can increase their risk of cardiovascular disease [ 72 ]. Thus, evaluation of secondary effects of these medications in clinical settings remains vitally important.…”

Section: Prospectivementioning

confidence: 99%

Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE+ B cells

Chen

et al. 2018

Clin Transl Allergy

View full text Add to dashboard Cite

Allergic diseases are inflammatory disorders that involve many types of cells and factors, including allergens, immunoglobulin (Ig)E, mast cells, basophils, cytokines and soluble mediators. Among them, IgE plays a vital role in the development of acute allergic reactions and chronic inflammatory allergic diseases, making its control particularly important in the treatment of IgE-mediated allergic diseases. This review provides an overview of the current state of IgE targeted therapy development, focusing on three areas of translational research: IgE neutralization in blood; IgE-effector cell elimination; and IgE+ B cell reduction. IgE-targeted medicines such as FDA approved drug Xolair (Omalizumab) represent a promising avenue for treating IgE-mediated allergic diseases given the pernicious role of IgE in disease progression. Additionally, targeted therapy for IgE-mediated allergic diseases may be advanced through cellular treatments, including the modification of effector cells.

show abstract

Section: Prospectivementioning

confidence: 99%

Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE+ B cells

Chen

et al. 2018

Clin Transl Allergy

View full text Add to dashboard Cite

show abstract

“…Levels of total IgE are >160 times greater in non-Western human populations which commonly experience helminth infection than in the USA [146]. A recent case-control study showed that adults with selective IgE deficiency (<2 IU/ml) had higher rates of arterial hypertension, peripheral vascular disease, ischemic heart disease, and carotid stenosis than matched controls [147]. …”

Section: Cardio-metabolic Protective Effects Of Helminth Infectionmentioning

confidence: 99%

Cardiovascular disease and type 2 diabetes in evolutionary perspective: A critical role for helminths?

Gurven

Trumble

Stieglitz

et al. 2016

EMPH

View full text Add to dashboard Cite

Heart disease and type 2 diabetes are commonly believed to be rare among contemporary subsistence-level human populations, and by extension prehistoric populations. Although some caveats remain, evidence shows these diseases to be unusual among well-studied hunter-gatherers and other subsistence populations with minimal access to healthcare. Here we expand on a relatively new proposal for why these and other populations may not show major signs of these diseases. Chronic infections, especially helminths, may offer protection against heart disease and diabetes through direct and indirect pathways. As part of a strategy to insure their own survival and reproduction, helminths exert multiple cardio-protective effects on their host through their effects on immune function and blood lipid metabolism. Helminths consume blood lipids and glucose, alter lipid metabolism, and modulate immune function towards Th-2 polarization—which combined can lower blood cholesterol, reduce obesity, increase insulin sensitivity, decrease atheroma progression, and reduce likelihood of atherosclerotic plaque rupture. Traditional cardiometabolic risk factors, coupled with the mismatch between our evolved immune systems and modern, hygienic environments may interact in complex ways. In this review, we survey existing studies in the non-human animal and human literature, highlight unresolved questions and suggest future directions to explore the role of helminths in the etiology of cardio-metabolic disease.

show abstract

“…Adverse side effects have been reported with omalizumab therapy, including anaphylaxis, cardiovascular and cerebrovascular events, and malignancy, and there are reports of associated risks of low IgE levels and autoimmunity or increased risk for parasitic disease. [32][33][34][35][36][37] The overall incidence of adverse events reported has been similar across studies between subjects receiving omalizumab versus placebo, and the majority of treatment-related adverse events, mostly cardiovascular and cerebrovascular, and risk of parasitic infections were mild or moderate in severity in treated subjects.…”

Section: Therapy With Aavrh10anti-higementioning

confidence: 79%

Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy

Pagovich

Wang

Chiuchiolo

et al. 2016

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Selective IgE deficiency and cardiovascular diseases

Abstract: Selective immunoglobulin E (IgE) deficiency (IgED) is defined as serum levels of IgE more than or equal to 2 kIU/L and is

Cited by 15 publications

References 32 publications

Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE+ B cells

Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE+ B cells

Cardiovascular disease and type 2 diabetes in evolutionary perspective: A critical role for helminths?

Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy

Contact Info

Product

Resources

About